Table 3.

Prognosis of IBD patients: EBV-DNA positive and EBV-DNA negative in blood, EBER-1 positive and EBER-1 negative in mucosa

	EBV-DNA			EBER
	+ (n=48)	− (n=520)	P	+ (n=27)	− (n=21)	P
Clinical remission within 3 months
UC n (n) (%)	20 (28) (71.4%)	175 (230) (76.1%)	0.558	13 (19) (68.4%)	7 (9) (77.8%)	0.609
CD n (n) (%)	13 (20) (65.0%)	220 (290) (75.9%)	0.277	4 (8) (50.0%)	7 (12) (58.3%)	0.714
Surgery within 3 months, n (%)	9 (18.8%)	93 (17.8%)	0.881	6 (22.2%)	3 (14.2%)	0.485
Lymphoma was observed during follow-up, n (%)	1 (2.1%)	1 (0.2%)	0.034	1 (3.7%)	0 (0.0%)	0.373
CAEBV was observed during follow-up, n (%)	0 (%)	0 (0.0%)	-	0 (0%)	0 (0.0%)	-

IBD, Inflammatory bowel disease; UC, ulcerative colitis; CD, Crohn’s disease; EBV, Epstein-Barr virus; EBER-1, Epstein-Barr virus-encoded small-RNA 1; CAEBV: chronic activity Epstein-Barr virus